Bank of New York Mellon’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-236,089
| Closed | -$11.2M | – | 4184 |
|
|
2025
Q3 | $11.2M | Sell |
236,089
-1,594
| -0.7% | -$77.2K | ﹤0.01% | 1869 |
|
|
2025
Q2 | $12.7M | Buy |
237,683
+25,018
| +12% | +$1.14M | ﹤0.01% | 1762 |
|
|
2025
Q1 | $8.61M | Buy |
212,665
+12,235
| +6% | +$519K | ﹤0.01% | 1924 |
|
|
2024
Q4 | $5.58M | Sell |
200,430
-6,414
| -3% | -$194K | ﹤0.01% | 2234 |
|
|
2024
Q3 | $5.93M | Sell |
206,844
-44,390
| -18% | -$1.16M | ﹤0.01% | 2210 |
|
|
2024
Q2 | $5.89M | Buy |
251,234
+61,988
| +33% | +$1.33M | ﹤0.01% | 2249 |
|
|
2024
Q1 | $4.78M | Buy |
189,246
+11,451
| +6% | +$275K | ﹤0.01% | 2346 |
|
|
2023
Q4 | $4.15M | Sell |
177,795
-322,450
| -64% | -$6.36M | ﹤0.01% | 2462 |
|
|
2023
Q3 | $25.3M | Buy |
500,245
+346,317
| +225% | +$16.1M | 0.01% | 1420 |
|
|
2023
Q2 | $7.19M | Buy |
153,928
+31,336
| +26% | +$1.44M | ﹤0.01% | 2122 |
|
|
2023
Q1 | $4.69M | Sell |
122,592
-17,890
| -13% | -$798K | ﹤0.01% | 2337 |
|
|
2022
Q4 | $7.7M | Buy |
140,482
+27,592
| +24% | +$1.18M | ﹤0.01% | 2084 |
|
|
2022
Q3 | $3.84M | Buy |
112,890
+26,813
| +31% | +$410K | ﹤0.01% | 2440 |
|
|
2022
Q2 | $814K | Buy |
86,077
+4,495
| +6% | +$46.9K | ﹤0.01% | 3312 |
|
|
2022
Q1 | $1.16M | Buy |
81,582
+2,793
| +4% | +$48.9K | ﹤0.01% | 3219 |
|
|
2021
Q4 | $1.67M | Buy |
78,789
+1,675
| +2% | +$37.2K | ﹤0.01% | 3101 |
|
|
2021
Q3 | $1.72M | Buy |
77,114
+7,393
| +11% | +$167K | ﹤0.01% | 3075 |
|
|
2021
Q2 | $1.73M | Buy |
69,721
+15,073
| +28% | +$423K | ﹤0.01% | 3089 |
|
|
2021
Q1 | $1.58M | Sell |
54,648
-5,584
| -9% | -$169K | ﹤0.01% | 3055 |
|
|
2020
Q4 | $1.55M | Sell |
60,232
-10,696
| -15% | -$298K | ﹤0.01% | 2987 |
|
|
2020
Q3 | $2.18M | Buy |
70,928
+30,240
| +74% | +$1.06M | ﹤0.01% | 2618 |
|
|
2020
Q2 | $1.01M | Buy |
40,688
+13,232
| +48% | +$302K | ﹤0.01% | 3110 |
|
|
2020
Q1 | $582K | Buy |
27,456
+8,488
| +45% | +$182K | ﹤0.01% | 3282 |
|
|
2019
Q4 | $421K | Buy |
18,968
+8,001
| +73% | +$166K | ﹤0.01% | 3674 |
|
|
2019
Q3 | $250K | Buy |
+10,967
| New | +$255K | ﹤0.01% | 3842 |
|
Other funds holding AKRO
Bank of New York Mellon's AKRO Position: Q4 2025 in Review
Bank of New York Mellon sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 236,089 shares — an estimated $11.2M sold.
Bank of New York Mellon first reported a position in AKRO in Q3 2019 and held it in 25 quarters. The position peaked at $25.3M in Q3 2023. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.
- Bank of New York Mellon reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
- Bank of New York Mellon sold 236,089 Akero Therapeutics shares in Q4 2025, an estimated $11.2M.
- Bank of New York Mellon first reported a position in Akero Therapeutics in Q3 2019 and held it in 25 quarters.
- Bank of New York Mellon's Akero Therapeutics position peaked at $25.3M in Q3 2023.
- 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.
Based on Bank of New York Mellon's 13F filing for Q4 2025, filed 10 Feb 2026.